Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
I actually made a comment addressing the car-centric layouts (and how it is basically impossible to walk anywhere in many parts of America) elsewhere in the thread here.